With the stock's current price at Rs 2819.60, GlaxoSmithKline Pharmaceuticals is navigating through market dynamics, ...

Drugmaker GSK (GlaxoSmithKline) has said it is “well positioned” to cope with any financial impact from changes to US tariff rules. It came as the FTSE 100 giant revealed a rise in sales as weakness ...

ICICI Securities recommended reduce rating on GlaxoSmithKline Pharmaceuticals with a target price of Rs 2,600 in its research ...

UnitedHealth CEO Andrew Witty is stepping down for personal reasons and the nation’s largest health insurer suspended its ...

Arizona sued drug manufacturer GlaxoSmithKline over what it calls deceptive practices involving the inhaled corticosteroid Flovent that endangered asthma patients. The lawsuit filed Thursday in ...

GlaxoSmithKline Pharmaceuticals, operating in the Pharmaceuticals sector and classified as a Midcap on the BSE, currently has its share price at ₹2827.05. The stock has experienced fluctuations ...

Looking at the universe of stocks we cover at Dividend Channel, on 5/16/25, Coca-Cola Europacific Partners plc (Symbol: CCEP), Smurfit Westrock plc (Symbol: SW), and Glaxosmithkline plc (Symbol ...

The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.

In a report released today, James Gordon from J.P. Morgan maintained a Sell rating on GlaxoSmithKline (GSK – Research Report), with a price target of £15.00. The company’s shares closed today ...

Deutsche Bank analyst Emmanuel Papadakis maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The company’s shares opened today at p1 ...

GlaxoSmithKline Pharmaceuticals Limited was erstwhile incorporated as Glindia Limited in November, 1924. The Company s name was changed to Glaxo (India) Limited from Glindia Limited in year 1987 ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...